In their latest antibody-drug conjugate (ADC) partnership, Genmab has gained rights to utilise Seattle Genetics’ auristatin-based ADC technology with HuMax®-AXL, a preclinical-stage antibody targeting the AXL receptor tyrosine kinase. AXL is expressed on multiple tumour types and is involved in multiple processes of tumour development and progression. The two companies formed similar collaborations in 2010 and 2011 for Genmab’s HuMax®-TF and HuMax®-CD74 programmes, respectively.